OBJECTIVE Trisomy 21 is associated with a flat face, which can now be quantified by measurement of the frontomaxillary facial (FMF) angle. The aim of this study was to examine whether in trisomy 21 fetuses fetal nuchal translucency (NT) thickness and maternal serum free ss-human chorionic gonadotropin (ss-hCG) and pregnancy-associated plasma protein-A (PAPP-A) are independent of the FMF angle, ...

Featured article: Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, et al. Maternal serum screening for Down’s syndrome in early pregnancy. BMJ 1988;297:883–7. The era of organized prenatal screening began in the mid-1970s with the discovery that maternal serum -fetoprotein (AFP) could be used as a screening test for neural tube defects. This discovery led to work on how screening...

BACKGROUND Maternal serum prenatal quadruple screening includes testing for alpha-fetoprotein (AFP), human chorionic gonadotrophin (hCG), unconjugated estriol (uE3), and dimeric inhibin A (DIA). We evaluated quadruple screening using an automated platform and looked for any ethnic differences in the median values of each marker. METHODS We measured the concentrations of each quadruple test an...

The aim of the present study was to evaluate the efficacy of the first trimester screening for Down syndrome (DS) in an unselected low-risk Finnish population. The study involved 4,617 women who attended screening between the 8th and 14th weeks of pregnancy in 1998-2000. They gave a blood sample for the measurement of pregnancy associated plasma protein A (PAPP-A) and free beta human chorionic ...

OBJECTIVE The purpose of this study was to perform a cost-effectiveness analysis that compared the first- and second- trimester screening tools for Down syndrome. STUDY DESIGN A decision tree was designed that compared four possible screens for Down syndrome: (1) current second- trimester expanded maternal serum alpha-fetoprotein test (AFP), (2) first-trimester nuchal translucency screen, (3)...

OBJECTIVE To develop models for prediction of pre-eclampsia (PE) based on maternal factors and biophysical and biochemical markers at 11-13 weeks' gestation. METHODS Screening study of singleton pregnancies at 11-13 weeks including 752 (2.2%) that subsequently developed PE and 32,850 that were unaffected by PE. Models were developed for the prediction of early PE, requiring delivery before 34...

AIM: This study aims to assess differences in the mean maternal Vitamin D levels between severe preeclampsia (SPE) and normal pregnant women at Dr. Zainoel Abidin Hospital Banda Aceh, Indonesia. METHODS: research was a case–control conducted Regional General Aceh. Pregnant with confirmed SPE pregnancies were involved study. The level of 25(OH)D3 assessed by taking serum samples examined enzyme ...

The decision to have an amniocentesis entails a trade-off between a risk of procedure associated miscarriage and the benefit of obtaining diagnostic information to identify Down syndrome or other chromosomal aneuploidy. Ideally, this trade-off is informed by first and second trimester pre-natal screening tests, such that women with low risk screening test results are not encouraged to have an a...

Technology in the prenatal setting is advancing at an exceptional rate, and these advancements will likely result in major changes to current pregnancy screening and testing paradigms. In Australia, prenatal testing is increasingly becoming a routine part of antenatal care and pregnant women are offered an assortment of screening and diagnostic tests, which give them information about their fet...

Background: The accretion of the placenta has now been identified as a major cause maternal morbidity and mortality.The condition is defined adhering abnormally to uterus. Aim study: goal this study was assess effectiveness grayscale ultrasonography 3D power Doppler in detecting accreta vs serum alpha-fetoprotein levels women who had previous caesarean sections. Patients Methods: After 36 weeks...